Assembly Biosciences Stock Price, News & Analysis (NASDAQ:ASMB) $0.76 +0.02 (+2.21%) (As of 11:21 AM ET) Add Compare Share Share Today's Range$0.72▼$0.7650-Day Range$0.65▼$1.2552-Week Range$0.64▼$1.78Volume97,139 shsAverage Volume653,471 shsMarket Capitalization$49.87 millionP/E RatioN/ADividend YieldN/APrice Target$1.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Assembly Biosciences MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside102.0% Upside$1.50 Price TargetShort InterestHealthy2.84% of Float Sold ShortDividend StrengthN/ASustainability-0.71Upright™ Environmental ScoreNews Sentiment0.05Based on 43 Articles This WeekInsider TradingSelling Shares$3,403 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.19) to ($1.23) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.25 out of 5 starsMedical Sector305th out of 960 stocksPharmaceutical Preparations Industry93rd out of 381 stocks 3.0 Analyst's Opinion Consensus RatingAssembly Biosciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $1.50, Assembly Biosciences has a forecasted upside of 102.0% from its current price of $0.74.Amount of Analyst CoverageAssembly Biosciences has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.84% of the float of Assembly Biosciences has been sold short.Short Interest Ratio / Days to CoverAssembly Biosciences has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Assembly Biosciences has recently decreased by 17.27%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAssembly Biosciences does not currently pay a dividend.Dividend GrowthAssembly Biosciences does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAssembly Biosciences has received a 74.27% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health", "Clinical research services for infectious diseases", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Assembly Biosciences is -0.71. Previous Next 1.7 News and Social Media Coverage News SentimentAssembly Biosciences has a news sentiment score of 0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 43 news articles for Assembly Biosciences this week, compared to 23 articles on an average week.MarketBeat FollowsOnly 1 people have added Assembly Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Assembly Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,403.00 in company stock.Percentage Held by InsidersOnly 4.40% of the stock of Assembly Biosciences is held by insiders.Percentage Held by InstitutionsOnly 19.92% of the stock of Assembly Biosciences is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Assembly Biosciences are expected to decrease in the coming year, from ($1.19) to ($1.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Assembly Biosciences is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Assembly Biosciences is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAssembly Biosciences has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Assembly Biosciences Stock (NASDAQ:ASMB)Assembly Biosciences, Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study. It is also involved in novel small molecule approaches for HBV and hepatitis delta virus (HDV) comprising an orally bioavailable HBV/HDV entry inhibitor and liver-focused interferon-a receptor agonist. In addition, the company develops Herpesvirus programs, such as ABI-5366 HSV-2, a long-acting helicase inhibitor; and pan-herpes non-nucleoside polymerase inhibitors for transplant-associated infections. Further, Assembly Biosciences, Inc. has collaboration agreement with BeiGene, Ltd. to develop and commercialize the novel core inhibitor product candidates for chronic HBV infection in the People's Republic of China, Hong Kong, Taiwan, and Macau; and clinical trial collaboration agreement with Arbutus Biopharma Corporation to conduct a randomized, multi-center, and open-label clinical trials, as well as agreement with Antios Therapeutics, Inc. for triple combination therapy. The company also has license agreement with Indiana University Research and Technology Corporation for HBV research, as well as a partnership with Gilead Sciences, Inc. to develop next-generation therapeutics for serious viral diseases. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.Read More ASMB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ASMB Stock News HeadlinesDecember 8, 2023 | msn.comAIMIM Leader Akbaruddin Owaisi Likely To Be Appointed As The Pro-Tem Speaker Of Telangana AssemblyDecember 7, 2023 | msn.comGOP Activist Carl DeMaio to Run for Assembly Seat, Quit KOGO Radio ShowDecember 8, 2023 | Financial Alphas (Ad)Countries Are Investing Heavily Into Securing Energy IndependenceThere's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.December 7, 2023 | news.yahoo.comWorst snow 'by far': Anchorage Assembly members and Bronson administration debate ways to improve plowingDecember 7, 2023 | msn.comNational Assembly to hold revote on four vetoed billsDecember 7, 2023 | msn.comCanada's Assembly of First Nations elects new leaderDecember 7, 2023 | msn.comUp to 1200 layoffs expected at Toledo Assembly Complex, Stellantis saysDecember 7, 2023 | msn.comGOP Activist and Former SD Councilman Carl DeMaio to Seek East County Assembly SeatDecember 8, 2023 | Financial Alphas (Ad)Countries Are Investing Heavily Into Securing Energy IndependenceThere's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.December 7, 2023 | news.yahoo.comComfort and joy: Seafood, warmth come together on new winter menu at The Jones AssemblyDecember 7, 2023 | msn.comAssembly of First Nations assembly continues without electing new national chiefDecember 7, 2023 | msn.comPolice stop Amaewhule faction from accessing Rivers State House of Assembly complexDecember 7, 2023 | msn.comMeeting on future of States AssemblyDecember 7, 2023 | msn.comDoctors Turn Netas: 15 Super Speciality Medics Becomes MLA After Big Win In Telangana Assembly Elections 2023December 6, 2023 | msn.comAssembly of First Nations election kicks off with no winner on 1st ballotDecember 6, 2023 | msn.comNo first-ballot winner as Assembly of First Nations seeks its next national chiefDecember 6, 2023 | msn.comNew Congressional maps head to General Assembly for final approvalDecember 6, 2023 | msn.comRivers Assembly gets new Majority Leader, Chief WhipDecember 6, 2023 | msn.comRivers Assembly crisis: Faction defies court order, holds sittingDecember 5, 2023 | msn.comQ&A: Assembly’s Labor committee chair prioritizes women, senior workersDecember 5, 2023 | msn.comGeorgia General Assembly Approves New Legislative MapsDecember 5, 2023 | msn.comMeet the candidates vying to be the national chief of the Assembly of First NationsDecember 5, 2023 | ca.news.yahoo.comAssembly of First Nations meeting kicks off as election of new national chief loomsDecember 5, 2023 | msn.comNasarawa Assembly passes N8.2bn 2023 Supplementary BudgetDecember 5, 2023 | msn.comAdamawa Assembly raises judicial officers’ retirement age to 65December 5, 2023 | msn.comAssembly of First Nations vote to elect new chief: Here’s what you need to knowDecember 5, 2023 | msn.comBJP's Assembly poll victories due to Centre's money power, agencies, EC, media: Mehbooba MuftiSee More Headlines Receive ASMB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Assembly Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2023Today12/08/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/27/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:ASMB CUSIP92282210 CIK1426800 Webwww.assemblybio.com Phone(833) 509-4583Fax646-706-5101Employees68Year Founded2005Price Target and Rating Average Stock Price Target$1.50 High Stock Price Target$1.50 Low Stock Price Target$1.50 Potential Upside/Downside+107.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-93,090,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-116.42% Return on Assets-95.89% Debt Debt-to-Equity RatioN/A Current Ratio6.96 Quick Ratio6.96 Sales & Book Value Annual Sales$6.25 million Price / Sales7.59 Cash FlowN/A Price / Cash FlowN/A Book Value$1.69 per share Price / Book0.43Miscellaneous Outstanding Shares65,709,000Free Float62,818,000Market Cap$47.46 million OptionableOptionable Beta0.50 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Jason A. Okazaki (Age 47)CEO, President & Director Comp: $869.28kDr. William E. Delaney IV (Age 51)Ph.D., Chief Scientific Officer Comp: $664.4kDr. Uri A. Lopatin M.D. (Age 51)Co-Founder and Clinical & Scientific Advisor Comp: $608.55kDr. Adam ZlotnickCo-Founder, Chief Scientific Advisor and Chair of Hbv & Virology Science Advisory BoardJeanette M BjorkquistExecutive Director of Accounting & TreasuryShannon RyanSenior Vice President of Investor Relations, Corporate Affairs & Alliance ManagementMs. Jennifer A. Troia MHRODSHRM-SCP, SPHR, Chief Human Resources OfficerDr. Nicole S. White Ph.D.Chief Manufacturing OfficerDr. Anuj Gaggar M.D.Ph.D., Chief Medical OfficerMr. Thomas E. Rollins (Age 67)Executive Officer Comp: $472.55kMore ExecutivesKey CompetitorsSol-Gel TechnologiesNASDAQ:SLGLCumberland PharmaceuticalsNASDAQ:CPIXNektar TherapeuticsNASDAQ:NKTRVYNE TherapeuticsNASDAQ:VYNEAeglea BioTherapeuticsNASDAQ:AGLEView All CompetitorsInsiders & InstitutionsHudson Bay Capital Management LPSold 626,466 shares on 12/7/2023Ownership: 0.304%Acadian Asset Management LLCSold 30,384 shares on 11/13/2023Ownership: 0.127%Jason A OkazakiSold 2,363 sharesTotal: $1,890.40 ($0.80/share)Nicole S WhiteSold 1,891 sharesTotal: $1,512.80 ($0.80/share)Jeanette M BjorkquistSold 844 sharesTotal: $903.08 ($1.07/share)View All Insider TransactionsView All Institutional Transactions ASMB Stock Analysis - Frequently Asked Questions Should I buy or sell Assembly Biosciences stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Assembly Biosciences in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ASMB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ASMB, but not buy additional shares or sell existing shares. View ASMB analyst ratings or view top-rated stocks. What is Assembly Biosciences' stock price target for 2024? 1 equities research analysts have issued 1-year price targets for Assembly Biosciences' stock. Their ASMB share price targets range from $1.50 to $1.50. On average, they anticipate the company's stock price to reach $1.50 in the next year. This suggests a possible upside of 102.0% from the stock's current price. View analysts price targets for ASMB or view top-rated stocks among Wall Street analysts. How have ASMB shares performed in 2023? Assembly Biosciences' stock was trading at $1.30 at the beginning of 2023. Since then, ASMB stock has decreased by 42.9% and is now trading at $0.7426. View the best growth stocks for 2023 here. Are investors shorting Assembly Biosciences? Assembly Biosciences saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 649,700 shares, a drop of 17.3% from the October 31st total of 785,300 shares. Based on an average trading volume of 1,880,000 shares, the short-interest ratio is presently 0.3 days. Approximately 2.8% of the company's shares are short sold. View Assembly Biosciences' Short Interest. When is Assembly Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024. View our ASMB earnings forecast. How were Assembly Biosciences' earnings last quarter? Assembly Biosciences, Inc. (NASDAQ:ASMB) issued its quarterly earnings data on Wednesday, November, 8th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.23) by $0.04. What is John McHutchison's approval rating as Assembly Biosciences' CEO? 8 employees have rated Assembly Biosciences Chief Executive Officer John McHutchison on Glassdoor.com. John McHutchison has an approval rating of 80% among the company's employees. 76.0% of employees surveyed would recommend working at Assembly Biosciences to a friend. What other stocks do shareholders of Assembly Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Assembly Biosciences investors own include BioDelivery Sciences International (BDSI), Exelixis (EXEL), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS), AVEO Pharmaceuticals (AVEO), Sorrento Therapeutics (SRNE), AbbVie (ABBV), BioCryst Pharmaceuticals (BCRX), Gilead Sciences (GILD) and Blueprint Medicines (BPMC). Who are Assembly Biosciences' major shareholders? Assembly Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Hudson Bay Capital Management LP (0.30%), Acadian Asset Management LLC (0.13%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Jacqueline Sybil Papkoff, Jason A Okazaki, Jeanette M Bjorkquist, John G Mchutchison, Luisa M Stamm, Michael P Samar, Nicole S White, Timothy A Springer, William E Iv Delaney and William E Iv Delaney. View institutional ownership trends. How do I buy shares of Assembly Biosciences? Shares of ASMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:ASMB) was last updated on 12/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Assembly Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.